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1  | INTRODUCTION
Cardiovascular disease (CVD) is a leading cause of premature 
mortality among middle‐aged and elderly individuals in both 
developing and developed countries.1,2 The burden of CVD has 
been reported to be a substantial determinant of a lower quality 
of life among the elderly. Therefore, early identification of indi‐
viduals at higher risk for CVD may allow utilization of preventive 
strategies important for slowing the development and progres‐
sion of CVD.
Calcium is a pervasive divalent cation that is involved in blood 
coagulation and muscle contraction as well as in skeletal mineraliza‐
tion and nerve excitability.3,4 Blood calcium concentration is mainly 
managed by the balance of calcitonin and parathyroid hormone and 
can be influenced by various factors such as diet, vitamin D level, 
and daily activity.5,6 Recently, accrued epidemiological data indicate 
that the concentration of circulating calcium is positively related to 
CVD morbidity and mortality in the general population.7‐9 There is 
also an emerging issue regarding the possible relationship between 
calcium supplements and increasing CVD risk.10,11
 
Received: 20 January 2019  |  Accepted: 8 March 2019
DOI: 10.1111/jch.13532  
O R I G I N A L  P A P E R
Borderline high serum calcium levels are associated with 
arterial stiffness and 10‐year cardiovascular disease risk 
determined by Framingham risk score
Byoungjin Park MD1,2  |   Yong‐Jae Lee MD, MPH, PhD1
1Department of Family Medicine, Yonsei 
University College of Medicine, Seoul, Korea
2Department of medicine, Graduate School 
of Medicine, Yonsei University, Seoul, Korea
Correspondence
Yong‐Jae Lee, MD, MPH, PhD, Associate 
Professor, Department of Family Medicine, 
Yonsei University College of Medicine, 
Seoul, Republic of Korea.
Email: ukyjhome@yuhs.ac
Abstract
Recent epidemiological data indicate that the concentration of circulating calcium is 
related to cardiovascular disease (CVD) mortality. We determined whether serum 
calcium level is related to arterial stiffness and 10‐year CVD risk calculated by 
Framingham risk score (FRS). We examined the association of normal‐range serum 
calcium level with arterial stiffness and FRS in 565 Korean adults participating at the 
Health Promotion Center of Gangnam Severance Hospital between March 2016 and 
May 2017. High brachial‐ankle pulse wave velocity (baPWV) was defined as 
>1460 cm/s, and high FRS was defined as ≥10 percent for 10‐year CVD risk. Odds 
ratios (ORs) and 95% confidence intervals (95% CIs) for high baPWV and high FRS 
were calculated using multiple logistic regression analysis after adjusting for con‐
founding variables. The OR (95% CI) for high baPWV was 3.91 (1.15‐7.36) per 1 mg/
dL increment of serum calcium after adjusting for age, sex, body mass index, smoking 
status, exercise regularity, alcohol consumption, mean blood pressure, fasting plasma 
glucose, triglyceride, HDL‐cholesterol, C‐reactive protein, γ‐glutamyltransferase, uric 
acid level, phosphate level, potassium level, and presence of hypertension, diabetes 
and dyslipidemia medications (P = 0.024). A positive association between serum cal‐
cium level and high FRS was also observed after adjusting for the same covariables 
(OR, 3.54 [95% CI, 1.01‐12.44], P = 0.048). Serum calcium level was independently 
and positively associated with baPWV and 10‐year CVD risk estimates. Early detec‐
tion of higher serum calcium level may be important for the assessment of arterial 
stiffness and future risk of a cardiovascular event.
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In this study, we hypothesized that the link between higher 
calcium concentrations and increased CVD risk may be explained 
by prolonged exposure of higher serum calcium to structural and 
functional changes within the arterial walls, resulting in arterial 
stiffness. To this end, we investigated the association of serum 
calcium level with arterial stiffness in Korean adults as measured 
by brachial‐ankle pulse wave velocity (baPWV) and Framingham 
risk score (FRS), a widely used metric to estimate global risk for a 
10‐year CVD event.
2  | METHODS
2.1 | Study population
We reviewed the medical records of 641 participants (366 males, 
275 females) who underwent a medical examination at the Health 
Promotion Center of Gangnam Severance Hospital, Yonsei University 
College of Medicine between March 2016 and May 2017. Subjects 
meeting any of the following criteria were excluded (n = 76): subjects 
with any missing covariate information, a history of coronary heart 
disease or stroke, subjects with C‐reactive protein concentration 
>10.0 mg/L (to rule out acute inflammatory disorders), and subjects 
with serum calcium concentration >10.5 mg/dL or <8.5 mg/dL (to 
rule out calcium homeostasis disorders). After exclusions, 565 par‐
ticipants (333 males, 232 females) were included in the final analysis. 
This study was approved by the Institutional Review Board of Yonsei 
University College of Medicine, and informed consent was obtained 
from each participant. The examinations were performed by medical 
staff according to standard procedures.
2.2 | Data collection
Participants were asked questions regarding their lifestyles and be‐
haviors, including whether they smoked cigarettes, consumed alco‐
hol, and engaged in physical activity (more or <2 times per week), as 
well as whether they were currently undergoing treatments for any 
disease. If so, they were asked for the date of diagnosis and a list 
of current medications. Trained staff reviewed the completed ques‐
tionnaires and entered responses into a database. Participants were 
classified as either non‐smokers, ex‐smokers, or current smokers and 
as non‐drinkers or current drinkers. Body mass index (BMI) was cal‐
culated for each participant as weight divided by height squared (kg/
m2). After a 12‐hour overnight fast, blood samples were collected 
from an antecubital vein. Fasting plasma glucose, total cholesterol, 
triglyceride, HDL‐cholesterol, γ‐glutamyltransferase, uric acid, cal‐
cium, and potassium levels were measured using a Hitachi 7600‐110 
Chemistry Autoanalyzer (Hitachi, Tokyo, Japan). High‐sensitivity C‐
reactive protein (CRP) concentration was measured with a Roche/
Hitachi 912 System (Roche Diagnostics, Indianapolis, IN, USA) using 
a latex‐enhanced immunoturbidimetric method with a lower limit 
of detection of 0.02 mg/L. A Type 2 diabetic was defined as a par‐
ticipant with a fasting plasma glucose level ≥ 126 mg/dL or currently 
using anti‐diabetes medication. Hypertension was defined as systolic 
blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, 
or currently using anti‐hypertension medication.
2.3 | BaPWV measurement
We used an automatic waveform analyzer (model BP‐203RPE; 
Colin Co., Komaki, Japan) to measure baPWV. This instrument 
simultaneously records a phonocardiogram, electrocardiogram, 
and arterial blood pressure at both brachial arteries as well as 
both ankles. After 10 minutes of bed rest, participants were ex‐
amined in the supine position. Electrocardiogram electrodes 
were placed on both wrists, and a microphone for the phonocar‐
diogram was placed on the left edge of the sternum. Pneumatic 
cuffs were wrapped around both upper arms and ankles and con‐
nected to a plethysmograph to determine the volume pulse wave‐
form. Waveforms for brachial and tibial arteries were stored for 
10‐second sample times with automatic gain analyses and qual‐
ity adjustments. Oscillometric pressure sensors were attached to 
the cuffs to measure blood pressure in the four extremities. The 
baPWVs were recorded using a semiconductor pressure sensor 
(1200 Hz sample acquisition frequency) and calculated using the 
following equation: (La‐Lb)/ΔTba, where La and Lb were defined as 
the distance from the aortic valve to the elbow and to the ankle, 
respectively, and the time interval between the arm and ankle dis‐
tance (ΔTba) was defined as the pulse transit time between the 
brachial and tibial arterial pressure waveforms. The distances 
from the suprasternal notch to the elbow (La) and to the ankle 
(Lb) were estimated automatically and expressed by the follow‐
ing equations: La = 0.2195 × participant height (cm) − 2.0734 and 
Lb = 0.8129 × participant height (cm) + 12.328.
2.4 | Framingham 10‐year risk estimation
Framingham risk score is a useful tool for predicting a patient’s risk 
of severe cardiovascular events up to 10 years after estimation. 
Equations used in risk estimation are based on the individual’s de‐
scription of their age, sex, current blood pressure, reported lipid 
profile, smoking status, and use of blood pressure lowering drugs. 
Categories of patient demographics used to calculate FRS were 
as follows: age—20‐34, 35‐39, 40‐44, 45‐49, 50‐54, 55‐59, 60‐64, 
65‐69, 70‐74, and 75‐79 years; sex—male or female; total choles‐
terol level—<160, 160‐199, 200‐239, 240‐279, and ≥280 mg/dL; 
HDL‐cholesterol level—≥60, 50‐59, 40‐49, and <40 mg/dL; smoking 
status—non‐smoker or ex‐smoker, and current smoker; and systolic 
blood pressure—<120, 120‐129, 130‐139, 140‐159, and ≥160 mm Hg 
according to the presence of hypertension treatment. Estimated risk 
for 10‐year CVD was classified as low risk (<10%) and intermediate 
risk or high risk (≥10%).12
2.5 | Statistical analysis
High baPWV was defined as >1460 cm/s, which corresponded to 
the 75th percentile of the current sample, and high FRS was defined 
670  |     PARK And LEE
as ≥10 percent for 10‐year CVD risk. We compared basic charac‐
teristics of each demographic group using independent two‐sample 
t‐tests for continuous variables (age, BMI, mean blood pressure, 
fasting plasma glucose, triglyceride, HDL‐cholesterol, CRP, γ‐gluta‐
myltransferase, uric acid, potassium, phosphate, and calcium levels) 
and a chi‐square test for categorical variables (sex, smoking status, 
alcohol consumption, rate of physical activity, use of hypertension 
medication, use of diabetes medication, and use of dyslipidemia 
medication). To determine whether an independent relationship ex‐
isted between serum calcium level and high baPWV or high FRS, 
we used multiple logistic regression analysis after adjusting for con‐
founding variables. All analyses were conducted in 2017‐2018, using 
SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC, 
USA). All statistical tests were two‐sided, and statistical significance 
was determined at P < 0.05.
3  | RESULTS
Tables 1 and 2 list the demographic and biochemical characteristics 
of the study sample (n = 565). The overall prevalence of high baPWV 
and high FRS was 25.4% and 24.2%, respectively. Mean calcium 
level was significantly higher in high baPWV and high FRS groups 
compared with the control group (P < 0.001 for both). Mean values 
for age, BMI, mean blood pressure, fasting plasma glucose, triglyc‐
erides, and CRP level were higher in the high baPWV group, but 
HDL‐cholesterol and alcohol consumption were higher for those in 
the control group. Similar patterns were seen in the high FRS group 
compared to the control group. Additionally, serum potassium and 
uric acid levels were higher in the high FRS group, without significant 
difference in alcohol consumption.
Table 3 shows the risk of high baPWV and high FRS according 
to changes in serum calcium level. After adjusting for age, sex, BMI, 
smoking status, exercise regularity, alcohol consumption, mean blood 
pressure, fasting plasma glucose, triglycerides, HDL‐cholesterol, 
TA B L E  1   Clinical characteristics of the subjects according to 
presence of high baPWV
 
Controls 
(n = 421)
High baPWV 
(n = 144) P
Age, y 44.7 (10.2) 57.9 (10.1) <0.001
Male sex, % 58.9 59.0 0.979
Body mass index, kg/m2 23.7 (2.9) 24.8 (2.5) <0.001
Current smoking, % 22.1 24.3 0.583
Ever smoking, % 22.8 22.9 0.977
Alcohol consumptiona , 
%
75.8 60.4 <0.001
Regular exerciseb , % 59.1 54.2 0.296
Mean blood pressure, 
mm Hg
86.1 (11.2) 98.2 (12.0) <0.001
Fasting plasma glucose, 
mg/dL
94.7 (18.4) 104.3 (26.4) <0.001
Triglyceride, mg/dL 107.5 (98.6) 145.3 (80.7) <0.001
HDL‐cholesterol, mg/dL 48.3 (12.8) 43.9 (10.4) <0.001
C‐reactive protein, 
mg/L
0.8 (1.1) 1.4 (1.8) <0.001
Serum calcium, mg/dL 9.3 (0.3) 9.4 (0.3) <0.001
Serum phosphate, mg/
dL
3.7 (0.5) 3.8 (0.5) 0.006
Serum potassium, 
mmol/L
4.6 (0.2) 4.7 (0.1) 0.714
γ‐glutamyltransferase, 
U/L
24.3 (16.1) 27.2 (15.6) 0.058
Uric acid, mg/dL 5.2 (1.4) 5.4 (1.2) 0.155
Hypertension 
medication, %
7.8 28.5 <0.001
Diabetes medication, % 2.9 10.4 <0.001
Dyslipidemia medica‐
tion, %
4.5 6.9 0.253
Data are expressed as the mean (SD) or percentage.
aAlcohol consumption ≥ 140 g/wk. 
bRegular exercise ≥ twice/wk. 
TA B L E  2   Clinical characteristics of the subjects according to 
presence of high FRS
 
Controls 
(n = 428)
High FRS 
(n = 137) P
Age, y 45.2 (10.9) 56.7 (9.6) <0.001
Male sex, % 51.9 7.3 <0.001
Body mass index, kg/m2 23.6 (2.9) 25.3 (2.4) <0.001
Current smoking, % 10.8 59.9 <0.001
Ever smoking, % 24.3 18.3 0.142
Alcohol consumptiona , % 71.5 73.0 0.734
Regular exerciseb , % 62.4 43.8 <0.001
Mean blood pressure, 
mm Hg
87.4 (12.7) 94.8 (10.5) <0.001
Fasting plasma glucose, 
mg/dL
93.2 (15.4) 109.2 (30.1) <0.001
Triglyceride, mg/dL 105.6 (95.9) 153.5 (85.8) <0.001
HDL‐cholesterol, mg/dL 48.8 (12.5) 42.1 (10.2) <0.001
Serum calcium, mg/dL 9.3 (0.3) 9.4 (0.3) <0.001
Serum phosphate, mg/dL 3.7 (0.5) 3.6 (0.5) 0.039
Serum potassium, 
mmol/L
4.0 (0.3) 4.1 (0.3) 0.037
C‐reactive protein, mg/L 0.8 (1.2) 1.2 (1.6) 0.009
γ‐glutamyltransferase, 
U/L
22.6 (14.9) 32.6 (17.0) <0.001
Uric acid, mg/dL 5.1 (1.4) 5.8 (1.2) <0.001
Hypertension medica‐
tion, %
7.9 29.2 <0.001
Diabetes medication, % 1.6 14.6 <0.001
Dyslipidemia medication, 
%
3.7 9.5 0.007
Data are expressed as the mean (SD) or percentage.
aAlcohol consumption ≥ 140 g/wk. 
bRegular exercise ≥ twice/wk. 
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CRP, γ‐glutamyltransferase, uric acid, phosphate, and potassium, 
the odds ratio (95% CI) for high baPWV was 2.70 (1.07‐6.80) and 
for high FRS was 3.66 (1.09‐12.29) per 1 mg/dL increment of serum 
calcium. These associations remained after adjusting for the pres‐
ence of medications that could modify vascular function parameters, 
including anti‐hypertension, anti‐diabetic drugs, and lipid‐lowering 
medications.
4  | DISCUSSION
For individuals without clinical calcium homeostasis disorders, our 
cross‐sectional study showed a positive association of serum cal‐
cium level with baPWV and 10‐year CVD risk estimates, independ‐
ent of classical cardiovascular risk factors. These effects remained 
after adjusting for the presence of vascular function‐modifying 
drugs such as anti‐hypertensive drugs, anti‐diabetic drugs, and dys‐
lipidemia medications.
Many previous studies have investigated the associations among 
circulating calcium level and overt vascular events and mortality.7‐9 A 
recent meta‐analysis of studies performed to assess the association 
between serum calcium level and coronary heart disease mortality 
showed that the hazard risk for death was 1.13 when serum calcium 
concentration increased by one standard deviation.8 Also, a prospec‐
tive study that examined 16 000 people over 12.6 years demonstrated 
that the hazard risk for stroke increased 1.37 units with each standard 
deviation increase in serum calcium concentration.9 A distinguishing 
feature of our study is that it examined the impact of serum calcium 
on vascular health status and future CVD risk in preclinical stage CVD. 
In our study, high baPWV was defined as >1460 cm/s, which has been 
shown to be a useful predictor of CVD.13 High FRS was defined as an 
estimated risk >10% for a 10‐year CVD event, which was classified as 
low risk (<10%) and intermediate risk or high risk (≥10%).12 Recently, 
the use of statin or aspirin has been proposed to prevent future CVD 
morbidity and mortality based on risk estimation of a 10‐year CVD 
event.14,15
Some biological mechanisms may help to explain associations 
of serum calcium with arterial stiffness and 10‐year CVD risk. 
Increased serum calcium level could induce alterations to blood 
coagulation mechanisms and lead to endothelial dysfunction, 
binding to calcium‐sensing receptors, or interaction with pyro‐
phosphates, which are important inhibitors of tissue calcification; 
higher serum calcium levels result in smaller concentrations of 
serum pyrophosphates and greater tissue calcification.11,16 Gene 
expression alterations may be induced by prolonged exposure 
to and increased concentration of circulating calcium in vascular 
smooth muscle cells, which can lead to mutations in calcium‐sens‐
ing receptors with subsequent enhanced cardiovascular risk.17,18 
Further, increased serum calcium level has also been shown to be 
related to a deteriorated lipid profile.19,20 It is also known that the 
higher is the intracellular free calcium level, a secondary messen‐
ger system, the greater are the catecholamine secretion, vasocon‐
strictor tone, and arterial blood pressure.21,22 Lastly, Vitamin D and 
parathyroid hormone (PTH) levels are involved in the relationship 
between serum calcium level and CVD.5,6 Vitamin D plays a role 
in regulating many genes for vascular health involving cell prolif‐
eration, apoptosis, oxidative stress, and cell adhesion and also can 
lead to activation of the renin‐angiotensin‐aldosterone system, 
predisposing the individual to high blood pressure and left ven‐
tricular remodeling. Furthermore, chronic vitamin D deficiency can 
induce elevation of PTH, which in turn increases vascular inflam‐
mation and may be implicated in adverse CVD events.23,24 Vitamin 
D deficiency is a worldwide epidemic and is not limited to East 
Asians.25‐27 In a nationally representative survey conducted by the 
Korean Ministry of Health and Welfare, 65.9% of men and 77.7% 
of women had <20 ng/mL of 25‐hydroxyvitamin D among Koreans 
aged 10 years or older.28
4.1 | Limitations
Our study had several limitations. Caution should be used in causal 
and temporal interpretations due to its cross‐sectional design. 
Further, study participants were volunteers visiting for health pro‐
motion screenings in a single hospital and appeared to be slightly 
healthier individuals than most community‐based cohorts, indicat‐
ing that the study population may not be representative of the gen‐
eral population. We did not take into consideration the effects of 
vitamin D and PTH because these biomarkers were not measured 
TA B L E  3   Multiple logistic regression analysis showing the independent contribution of serum calcium level to high baPWV and high FRS
 
High baPWV High FRS
OR (95% CIs) P OR (95% CIs) P
Model 1a  4.00 (1.86‐8.61) <0.001 3.98 (1.66‐9.53) 0.002
Model 2b  2.70 (1.07‐6.80) 0.035 3.66 (1.09‐12.29) 0.036
Model 3c  3.91 (1.15‐7.36) 0.024 3.54 (1.01‐12.44) 0.048
aModel 1: adjusted for age and sex. 
bModel 2: adjusted for age, sex, body mass index, smoking status, alcohol consumption, regular exercise, mean blood pressure, fasting plasma glucose, 
triglyceride, HDL‐cholesterol, C‐reactive protein, γ‐glutamyltransferase, uric acid, phosphate, and potassium levels. 
cModel 3: adjusted for age, sex, body mass index, smoking status, alcohol consumption, regular exercise, hypertension medication, diabetes medica‐
tion, dyslipidemia medication, mean blood pressure, fasting plasma glucose, triglyceride, HDL‐cholesterol, C‐reactive protein, γ‐glutamyltransferase, 
uric acid, phosphate, and potassium levels. 
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at the beginning of this study, although chronic vitamin D deficiency 
has been a prevalent and nationwide problem over the last decade 
in Korea. Lastly, genetic susceptibility factors in calcium metabolism 
were not considered. To minimize genetic effects on calcium homeo‐
stasis, we excluded individuals with serum calcium >10.5 mg/dL or 
<8.5 mg/dL.
5  | CONCLUSION
We found serum calcium level to be independently and positively as‐
sociated with baPWV, a surrogate for arterial stiffness, and 10‐year 
CVD risk estimates calculated by FRS. This finding suggests that it 
may be possible to slow the development and progression of CVD 
in individuals with borderline high serum calcium level by practicing 
preventive strategies.
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